Publications by authors named "Robert McEwen"


STK11 (LKB1) mutations in metastatic NSCLC: Prognostic value in the real world.

PLoS One 2020 3;15(9):e0238358. Epub 2020 Sep 3.

Division of Hematology and Oncology, Columbia University Medical Center, New York, NY, United States of America.

View Article and Find Full Text PDF
October 2020

AKT Inhibition in Solid Tumors With AKT1 Mutations.

J Clin Oncol 2017 Jul 10;35(20):2251-2259. Epub 2017 May 10.

David M. Hyman, Lillian M. Smyth, Mark T.A. Donoghue, Matthew T. Chang, Jonathan B. Reichel, Nancy Bouvier, S. Duygu Selcuklu, Tara E. Soumerai, Jean Torrisi, Joseph P. Erinjeri, Michael F. Berger, Sarat Chandarlapaty, David B. Solit, José Baselga, and Barry S. Taylor, Memorial Sloan Kettering Cancer Center; David B. Solit, Weill Cornell Medical College, Cornell University, New York, NY; J. Carl Barrett and Brian Dougherty, AstraZeneca, Waltham, MA; Helen Ambrose, Andrew Foxley, Justin P.O. Lindemann, Robert McEwen, Martin Pass, and Gaia Schiavon, AstraZeneca, Cambridge; Emma J. Dean, The Christie National Health Service Foundation, Manchester; Udai Banerji, Royal Marsden Hospital, London, United Kingdom; Shannon N. Westin, The University of Texas MD Anderson Cancer Center, Houston, TX; Philippe L. Bedard, Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Hideaki Bando, National Cancer Center East Hospital, Kashiwa, Japan; Anthony B. El-Khoueiry, University of Southern California Norris Comprehensive Cancer Center; Alain Mita, Cedars-Sinai Medical Center, Los Angeles, CA; José A. Pérez-Fidalgo, Hospital Clinico de Valencia, Valencia, Spain; and Jan H.M. Schellens, Netherlands Cancer Institute, Amsterdam, the Netherlands.

View Article and Find Full Text PDF
July 2017